Rik J. Scheper spends much of his time researching Immunology, Molecular biology, Pathology, P-glycoprotein and Multiple drug resistance. His research on Immunology often connects related areas such as Cancer research. His Molecular biology study integrates concerns from other disciplines, such as FANCF, CD40, FANCA, Transmembrane protein and Membrane glycoproteins.
His Pathology research includes themes of ABCC6 and Drug resistance. His studies deal with areas such as Daunorubicin, NeuN, Transport protein and Blood–brain barrier as well as P-glycoprotein. Rik J. Scheper combines subjects such as Cell culture, Internal medicine, Gene and Multidrug resistance-associated protein 2 with his study of Multiple drug resistance.
Rik J. Scheper mostly deals with Immunology, Cancer research, Molecular biology, Cell biology and T cell. His Cancer research research is multidisciplinary, incorporating elements of Cell culture, P-glycoprotein, Multiple drug resistance, Pathology and Immunotherapy. His work carried out in the field of P-glycoprotein brings together such families of science as Daunorubicin and Abcg2.
His Multiple drug resistance research incorporates elements of Efflux and Pharmacology. In his study, Immunohistochemistry is strongly linked to Monoclonal antibody, which falls under the umbrella field of Molecular biology. The various areas that Rik J. Scheper examines in his T cell study include T lymphocyte and Cytokine.
Rik J. Scheper mainly investigates Immunology, Cell biology, Cancer research, Immunotherapy and T cell. His Cytotoxic T cell research extends to Immunology, which is thematically connected. His Cell biology research incorporates themes from Langerhans cell, Cell culture, Keratinocyte, Dermis and Human skin.
His research on Dermis also deals with topics like
The scientist’s investigation covers issues in Immunology, Cell biology, Dendritic cell, Immune system and Immunotherapy. His Immunology study incorporates themes from Cancer, Cancer research, In vitro, Dermis and Epidermis. His research investigates the connection between Cancer research and topics such as PSMB6 that intersect with problems in Proteasome inhibitor.
His work carried out in the field of Cell biology brings together such families of science as Cell culture, CCL21, Pathology, CXC chemokine receptors and Human skin. Rik J. Scheper has included themes like Oral administration, Placebo, Hepatitis and Sensitization in his Immune system study. His Molecular biology research focuses on Proteasome and how it relates to T cell and Cytokine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene.
Coen C. Paulusma;Piter J. Bosma;Guido J. R. Zaman;Conny T. M. Bakker.
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria
Johan W. Jonker;Marije Buitelaar;Els Wagenaar;Martin A. van der Valk.
Proceedings of the National Academy of Sciences of the United States of America (2002)
The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.
G.J.R. Zaman;M.J. Flens;M.R. van Leusden;M. de Haas.
Proceedings of the National Academy of Sciences of the United States of America (1994)
The drug resistance-related protein LRP is the human major vault protein
George L. Scheffer;Peter L.J. Wijngaard;Marcel J. Flens;Miguel A. Izquierdo.
Nature Medicine (1995)
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
Giuseppe Giaccone;Cornelis J. A. Punt;Yoshitaka Ando;Rita Ruijter.
Clinical Cancer Research (2002)
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial
Jan B Vermorken;Anke M E Claessen;Harm van Tinteren;Helen E Gall.
The Lancet (1999)
Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.
Jan Hendrik Hooijberg;Henk J. Broxterman;Marcel Kool;Yehuda G. Assaraf.
Cancer Research (1999)
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs
J Wijnholds;C A Mol;L van Deemter;M de Haas.
Proceedings of the National Academy of Sciences of the United States of America (2000)
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.
Thomas P. Miller;Thomas M. Grogan;William S. Dalton;Catherine M. Spier.
Journal of Clinical Oncology (1991)
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Ruud Oerlemans;Niels E. Franke;Yehuda G. Assaraf;Jacqueline Cloos.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: